Humira continues to be one of the most widely prescribed drugs in America with list prices that can exceed $80,000 per patient annually. Although commonly prescribed, Humira is not typically considered to be the first-line treatment for the conditions it is approved to treat, meaning alternative Rx options are available, and a versatile cost-containment strategy is a must!

Since the launch of Humira biosimilars in the US, TrueScripts has embraced these new products as an option to reduce costs for plan sponsors and members. Our biosimilar strategy prioritizes simplicity, offering a streamlined process with preferred biosimilars that deliver the same high-quality care as branded biologics—but at a significantly lower cost. By reducing confusion and providing clear choices, we ensure our clients benefit from meaningful savings, while members continue to receive uninterrupted care.

Here’s how we make it happen:

 
Transition to Yuflyma

Yuflyma (adalimumab-aaty) is a latex and citrate-free Humira biosimilar approved by the FDA to treat nearly all the same conditions as its reference product.

By leveraging unrestrained pharmacy contracting options, TrueScripts has developed a unique Humira savings strategy by partnering with a specialty pharmacy that can supply Yuflyma at a reduced cost. Through this partnership, a new non-branded Yuflyma (adalimumab-aaty) is offered to TrueScripts clients at a fixed rate of $800 to the plan and $0 to the member—achieving further savings from Yuflyma at $1,200.

Pursuing the Lowest Net Cost

As a full pass-through and conflict-free PBM, TrueScripts is not incentivized to “stack” our formularies with high-cost drugs solely to chase rebates. Instead, we focus on achieving the lowest net cost (including rebates).

For Humira, even with rebates considered, the adoption of Yuflyma yields more significant savings for plan sponsors. This is why our preferred biosimilar strategy is supported by a $0 copay, helping members access treatment without financial barriers.

In instances where transitioning to Yuflyma is not an option, TrueScripts will consider alternative savings options such as other biosimilars, international sourcing, copay cards, and more to achieve the lowest net cost of the necessary medication for each patient.

Guided Support
TrueScripts makes the switch to Yuflyma easy by working directly with patients and their physicians, helping them understand the benefits of biosimilars. Our dedicated team provides personalized support to ensure members understand their options and feel confident in the switch.

TrueScripts clients can rely on our clinical team to monitor ever-changing market conditions and make program adjustments to ensure optimized plan performance, maximized savings, and minimized disruption. With full access to data, clients can see the impact of adopting biosimilars on their plans.
 
What’s Next?
The biosimilar market will continue to expand, and TrueScripts is ready! We’re prepared to help clients capture savings as new biosimilars become available—from Stelara starting in 2025 to upcoming launches for Prolia and more. Our forward-looking and clinically-focused approach means that you’ll always have access to the most affordable and efficient options as soon as they become available.

To learn more about how TrueScripts can help you save on specialty drugs while keeping care first, contact us today. Together, we can bring transparency, savings, and simplicity to pharmacy benefits.